1 / 33

IMPROVING EARLY DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS

IMPROVING EARLY DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS. Michael Lockwood, MD, FACP, FACR Rheumatology Indiana University Health Arnett. Presentation of Case. March 1994: 48 yo w F smoker, joint pain and swelling, RF 74 June 1994 started hydroxychloroquin

arty
Download Presentation

IMPROVING EARLY DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IMPROVING EARLY DIAGNOSIS AND TREATMENT OF RHEUMATOID ARTHRITIS Michael Lockwood, MD, FACP, FACR Rheumatology Indiana University Health Arnett

  2. Presentation of Case • March 1994: 48 yo w F smoker, joint pain and swelling, RF 74 • June 1994 started hydroxychloroquin • September 1994 feeling much better • May 1998 started methotrexate • April 2002 found benefit with COX 2 Selective NSAIDs • August 2002 deformity and nodulosis • 2005 methotrexate was increased • May 2006: DAS 4.02, Hand films • January 2007: Infliximab started • Could a different outcome have been achieved?

  3. 11/25/1996 8/19/2006

  4. Rheumatoid Arthritis CureWhy is it important? • Severe disability after 20 year: 19% • Lifetime Costs: $225,000 - $370, 000 • Excess Deaths: Mortality Ratio = 2.26 • Excess Cardiovascular events = 4x • Increases risk of coronary artery disease = Type 2 diabetes Wolfe, A&R 37(4), p. 481

  5. Rheumatoid ArthritisApproach to Therapy Timing • Before 4 months: • Combination 42% • Single Drug 35% • After 4 months • Combination 42% • Single Drug 11% Mottonen, A&R, vol. 46, pp.894-98 Korpela, A&R vol. 50, pp 2072-81

  6. Rheumatoid ArthritisAdvantage of Early Assessment Timing Van der Linden, A&R Vol. 62 pp 3537-3547

  7. Rheumatoid Arthritis History • Onset: Weeks to Months • Can be Palindromic onset • Can have pauciarticular onset • Constitutional features • Morning stiffness lasting for hours • Functional Questions

  8. Rheumatoid Arthritis Epidemiology • Women:Men 3:1 • Peak onset age 30-55 • Incidence 30/100,000 • Prevalence • 1% Caucasians • 0.1% rural Africans

  9. Rheumatoid Arthritis Physical

  10. Rheumatoid Arthritis Physical

  11. Rheumatoid Arthritis Deformities Ulnar Deviation Swan neck deformities Boutenaire deformities

  12. Rheumatoid Arthritis Deformities Bayonet Deformities MTP Subluxation

  13. Rheumatoid Arthritis Deformities Atlantoaxial Instability MRI

  14. Rheumatoid Arthritis Extraarticular Involvement Rheumatoid Nodules

  15. Rheumatoid Arthritis Extraarticular Involvement Rheumatoid Vasculitis

  16. Rheumatoid Arthritis Extraarticular Involvement • Pulmonary • Pleurasy

  17. Rheumatoid Factor • Antibodies to Fc portion of IgG • 75-80% of Patients have during course of disease • Useful for prognosis

  18. Cyclic Citrullinated PeptideAntibodies (anti CCP) Schellekens, A&R, Vol 43, pp. 155-163

  19. Rheumatoid Arthritis X-Ray

  20. Rheumatoid Arthritis X-Ray

  21. Rheumatoid ArthritisClassification 1987 Criteria Arnett, A&R, Vol 31, pp. 315-324

  22. Rheumatoid ArthritisClassification 2010 Criteria Aletaha, A&R, Vol 62, pp. 2569-2581

  23. Rheumatoid ArthritisPathology

  24. Pathogenesis of Rheumatoid Arthritis Choy, E. H.S. et al. N Engl J Med 2001;344:907-916

  25. Rheumatoid ArthritisPannus

  26. Rheumatoid ArthritisApproach to Therapy Triple Drug Therapy • Triple Drug: 77% get 50 % improvement • Methotrexate: 33% • Plaquenil/Sulfasalazine: 40% O’Dell, NEJM vol. 334, pp 1287-1291

  27. Cytokine Signaling Pathways Involved in Inflammatory Arthritis Choy, E. H.S. et al. N Engl J Med 2001;344:907-916

  28. Rheumatoid Arthritis How do we proceed? • Aggressive approach, <5 yr disease, monthy followup • DAS calculated monthly • Aggressively escalating therapy • Goal: DAS remission or low disease activity • Results: ACR 50 = 84% vs 40% standard tx. • Decrease erosions • Total Costs less Grigor, Lancet, Vol. 364, pp. 263-269

  29. Rheumatoid Arthritis Implementation DAS scoring & aggressive approach in a community rheumatology practice

  30. Problem 1 A 32 year old man presents with fatigue, low back pain and morning stiffness lasting 15 minutes. He notes that the back pain seems to get worse as he works through his day. He is a machinist at a local factory. What should you do next? • Start a Medrol (methylprednisolone) dose pack • Check a rheumatoid factor (RF), cyclic citrullinated peptide antibody (CCP), and an antinuclear antibody (ANA) • Refer to physical therapy for back strengthening and instruction in back protection • Get a lumbar sacral xray 3 views • Get a MRI of the back.

  31. Problem 2 A 26 year old women presents with a 4 week history of swelling and tenderness of all of the MCPs, PIPs and the MTPs of the feet. This is confirmed on physical examination. There are no other stigmata on examination. Her labs are remarkable for a sed rate of 35 but a negative rheumatoid factor (RF), CCP, and ANA. Her hand a feet xrays are normal. Her most likely diagnosis is: • Systemic lupus erythematosus • Rheumatoid arthritis • Psoriatic arthritis • Fibromyalgia

  32. Problem 3 What treatment would you initiate for the above patient? • Monotherapy with methotrexate, hydroxychloroquin, or sulfasalazine but follow serial DAS (disease activity score) and treat to target. • Combination therapy with methotrexate, hydroxychloroquin, and sulfasalazine but follow serial DAS (disease activity score) and treat to target. • Combination therapy with methotrexate and a TNF blocker but follow serial DAS and treat to target.

  33. Problem 4 A 45 year old women presents with swelling and pain in the joints of 8 months duration, morning stiffness lasting several hours, and she finds it difficult to do her work. She has swelling and tenderness in most of the MCPs, PIPs, and MTPs. There is also swelling of the wrist, ankles, elbows, and one knee. Her sed rate is 60, and she has a high titre positive rheumatoid factor and cyclic citrullinated peptic (CCP). The ANA is 1:160. Her hand films do show joint space narrowing in one of the MCP and there is an erosion of a couple of the PIP. What treatment would you initiate for the patient? • Monotherapy with methotrexate, hydroxychloroquin, or sulfasalazine but follow serial DAS (disease activity score) and treat to target • Combination therapy with methotrexate, hydroxychloroquin, and sulfasalazine but follow serial DAS (disease activity score) and treat to target. • Combination therapy with methotrexate and a TNF blocker but follow serial DAS and treat to target

More Related